Raymond James Financial Inc. Acquires Shares of 404,461 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Raymond James Financial Inc. purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 404,461 shares of the medical equipment provider's stock, valued at approximately $36,183,000. Raymond James Financial Inc. owned 0.58% of Lantheus as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Groupama Asset Managment purchased a new stake in shares of Lantheus in the 3rd quarter valued at approximately $439,000. Swedbank AB raised its position in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares during the period. Keybank National Association OH acquired a new position in Lantheus during the fourth quarter worth $27,526,000. Janus Henderson Group PLC boosted its position in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after buying an additional 257,022 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus in the third quarter valued at $25,955,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Up 1.6 %

Lantheus stock traded up $1.66 during midday trading on Monday, reaching $102.76. The company's stock had a trading volume of 492,160 shares, compared to its average volume of 941,283. The company has a market cap of $7.04 billion, a P/E ratio of 17.10 and a beta of 0.38. The business has a 50-day simple moving average of $92.07 and a 200-day simple moving average of $96.68. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of research reports. Truist Financial increased their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $132.86.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.